Hematopoietic stem cell transplantation for myelofibrosis: Where are we now?

Current Opinion in Hematology

Volumn 20, Issue 2, 2013, Pages 130-136

  Fleischman, Angela G ^a   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

allogeneic transplantation; Janus kinase 2; myelofibrosis; ruxolitinib

Indexed keywords

GAMMA INTERFERON; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; INTERLEUKIN 6; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; JANUS KINASE INHIBITOR; MOMELOTINIB; RUXOLITINIB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; CANCER SURVIVAL; DECISION MAKING; ERYTHROCYTE TRANSFUSION; FEVER; GAIN OF FUNCTION MUTATION; GENE MUTATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOTE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NIGHT SWEAT; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; SPLENECTOMY; SPLENOMEGALY; SYMPTOM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

DECISION MAKING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PATIENT SELECTION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; TRANSPLANTATION CONDITIONING;

EID: 84873408936     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835dd862     Document Type: Review

References (37)

1. Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-916.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061.
3. James C, Ugo V, Le Coué dic J, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-1790.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397.
6. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788-22792.
7. Bogani C, Guglielmelli P, Antonioli E, et al. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica 2007; 92:258-259.
8. Jamieson CHM, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006; 103:6224-6229.
9. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29:1356-1363.
10. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363:1117-1127.
11. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115:5232-5240.
12. Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 2012; 36:1387-1392.
13. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119:3219-3225.
14. Fleischman AG, Aichberger KJ, Luty SB, et al. TNFa facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011; 118:6392-6398.
15. Ditschkowski M, Elmaagacli AH, Trenschel R, et al. DIPSS scores, pretransplant therapy and chronic GVHD determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica 2012; 97:1574-1581.
16. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703-1708.
17. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392-397.
18. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo clinic study of 884 karyotypically annotated patients. Blood 2011; 118:4595-4598.
19. Ditschkowski M, Beelen DW, Trenschel R, et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34:807-813.
20. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29:2230-2239.
21. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366:787-798.
22. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799-807.
23. Alessandro M. Vannucchi AM, Kiladjian J-J, et al. Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase II study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT) [abstract]. J Clin Oncol 2012; 30:abstr 6514.
24. Deeg HJ, Guardiola P. Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. Int J Hematol 2002; 76 (Suppl 2):29-34.
25. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Socié té Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 1999; 93:2831-2838.
26. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32:35-40.
27. Abelsson J, Merup M, Birgega° rd G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2011; 47:380-386.
28. Gupta V, Ahn KW, Zhu X, et al. Lille scoring system rather than DIPSS is a better predictive of overall mortality after allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis using reduced intensity conditioning: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR) [abstract]. American Society of Hematology Annual Meeting; 2012. Abstr. 42.
29. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107:361-370.
30. Ito T, Akagi K, Kondo T, et al. Splenic irradiation as a component of a reducedintensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly. Tohoku J Exp Med 2012; 228:295-299.
31. Stein BL, WilliamsDM, Rogers O, et al. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2V617F-positive myeloproliferative neoplasm patients. Exp Hematol 2011; 39:95-101.
32. Passamonti F, Vanelli L, Malabarba L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 2003; 88:1123-1129.
33. Andréasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34\+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2002; 68:189-193.
34. Carobbio A, Finazzi G, Thiele J, et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012; 87:203-204.
35. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26:475-480.
36. Sidon P, El Housni H, Dessars B, et al. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20:1622.
37. Krö ger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109:1316-1321.